Patents by Inventor B. Michael Longenecker

B. Michael Longenecker has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MUCINOUS GLYCOPROTEIN (MUC-1) VACCINE
    Publication number: 20160082093
    Abstract: The present invention provides a method for treating an individual who is afflicted with a cancer, such as non-small cell lung cancer or prostate cancer, by administering to that individual a MUC-1 based formulation. The formulation may be a MUC-1 based liposomal vaccine formulation.
    Type: Application
    Filed: September 25, 2015
    Publication date: March 24, 2016
    Inventor: B. Michael LONGENECKER
  • Method of Treating Patients with a Mucinous Glycoprotein (MUC-1) Vaccine
    Publication number: 20150359868
    Abstract: The present invention provides a method for treating an individual who is afflicted with a cancer, such as non-small cell lung cancer or prostate cancer, by administering to that individual a MUC-1-based formulation. The formulation may be a MUC-1 based liposomal vaccine formulation.
    Type: Application
    Filed: August 27, 2015
    Publication date: December 17, 2015
    Inventor: B. Michael LONGENECKER
  • Mucinous glycoprotein (MUC-1) vaccine
    Patent number: 9173929
    Abstract: The present invention provides a method for treating an individual who is afflicted with a cancer, such as non-small cell lung cancer or prostate cancer, by administering to that individual a MUC-1 based formulation. The formulation may be a MUC-1 based liposomal vaccine formulation.
    Type: Grant
    Filed: April 1, 2005
    Date of Patent: November 3, 2015
    Assignee: ONCOTHYREON INC.
    Inventor: B. Michael Longenecker
  • Method of treating patients with a mucinous glycoprotein (MUC-1) vaccine
    Patent number: 9119784
    Abstract: The present invention provides a method for treating an individual who is afflicted with a cancer, such as non-small cell lung cancer or prostate cancer, by administering to that individual a MUC-1-based formulation. The formulation may be a MUC-1 based liposomal vaccine formulation.
    Type: Grant
    Filed: September 17, 2014
    Date of Patent: September 1, 2015
    Assignee: ONCOTHYREON INC.
    Inventor: B. Michael Longenecker
  • Method of Treating Patients with a Mucinous Glycoprotein (MUC-1) Vaccine
    Publication number: 20150071990
    Abstract: The present invention provides a method for treating an individual who is afflicted with a cancer, such as non-small cell lung cancer or prostate cancer, by administering to that individual a MUC-1-based formulation. The formulation may be a MUC-1 based liposomal vaccine formulation.
    Type: Application
    Filed: September 17, 2014
    Publication date: March 12, 2015
    Inventor: B. Michael LONGENECKER
  • Method of treating patients with a mucinous glycoprotein (MUC-1) vaccine
    Patent number: 8871250
    Abstract: The present invention provides a method for treating an individual who is afflicted with a cancer, such as non-small cell lung cancer or prostate cancer, by administering to that individual a MUC-1-based formulation. The formulation may be a MUC-1 based liposomal vaccine formulation.
    Type: Grant
    Filed: June 27, 2006
    Date of Patent: October 28, 2014
    Assignee: Oncothyreon Inc.
    Inventor: B. Michael Longenecker
  • Vaccine for modulating between T1 and T2 immune responses
    Patent number: 8552145
    Abstract: The present invention provides liposomal vaccines containing immunogenic lipopeptides that are capable of modulating the humoral and cellular immune responses in vivo.
    Type: Grant
    Filed: May 2, 2012
    Date of Patent: October 8, 2013
    Assignee: Oncothyreon Inc.
    Inventors: Wladyslaw A. Budzynski, R. Rao Koganty, Mark J. Krantz, B. Michael Longenecker
  • Vaccine for Modulating Between T1 and T2 Immune Responses
    Publication number: 20120269884
    Abstract: The present invention provides liposomal vaccines containing immunogenic lipopeptides that are capable of modulating the humoral and cellular immune responses in vivo.
    Type: Application
    Filed: May 2, 2012
    Publication date: October 25, 2012
    Inventors: Wladyslaw A. Budzynski, R. Rao Koganty, Mark J. Krantz, B. Michael Longenecker
  • Vaccine for Modulating Between T1 and T2 Immune Responses
    Publication number: 20120269885
    Abstract: The present invention provides liposomal vaccines containing immunogenic lipopeptides that are capable of modulating the humoral and cellular immune responses in vivo.
    Type: Application
    Filed: May 2, 2012
    Publication date: October 25, 2012
    Inventors: Wladyslaw A. Budzynski, R. Rao Koganty, Mark J. Krantz, B. Michael Longenecker
  • Vaccine for modulating between T1 and T2 immune responses
    Patent number: 8198400
    Abstract: The present invention provides liposomal vaccines containing immunogenic lipopeptides that are capable of modulating the humoral and cellular immune responses in vivo.
    Type: Grant
    Filed: March 27, 2002
    Date of Patent: June 12, 2012
    Assignee: Oncothyreon, Inc.
    Inventors: Wladyslaw A. Budzynski, R. Rao Koganty, Mark J. Krantz, B. Michael Longenecker
  • Mucinous Glycoprotein (Muc-1) Vaccine
    Publication number: 20080131495
    Abstract: The present invention provides a method for treating an individual who is afflicted with a cancer, such as non-small cell lung cancer or prostate cancer, by administering to that individual a MUC-1 based formulation. The formulation may be a MUC-1 based liposomal vaccine formulation.
    Type: Application
    Filed: April 1, 2005
    Publication date: June 5, 2008
    Applicant: Biomira, Inc.
    Inventor: B. Michael Longenecker
  • Imunogenic conjugate of carbohydrate haptens and aggregated protein carrier
    Publication number: 20040247608
    Abstract: A conjugate of a plurality of carbohydrate haptens and an aggregate (multimer) of monomeric units of a carrier moiety is provided. The conjugate may be used to elicit an immune response. The conjugate is preferably a carbohydrate-substituted aggregate of KLH monomers, in particular, a dimeric, trimeric or tetrameric aggregated. An aggregated STn-KLH conjugate is of particular interest.
    Type: Application
    Filed: July 23, 2004
    Publication date: December 9, 2004
    Inventors: Mark J Krantz, B. Michael Longenecker, R. Rao Koganty, Ting Chi Wong
  • Vaccine for modulating between T1 and T2 immune responses
    Publication number: 20030157160
    Abstract: The present invention provides liposomal vaccines containing immunogenic lipopeptides that are capable of modulating the humoral and cellular immune responses in vivo.
    Type: Application
    Filed: March 27, 2002
    Publication date: August 21, 2003
    Applicant: BIOMIRA, INC.
    Inventors: Wladyslaw A. Budzynski, R. Rao Koganty, Mark J. Krantz, B. Michael Longenecker
  • Methods of detecting T-cell activation
    Patent number: 6602660
    Abstract: Methods of detecting activated T-cells involve monitoring levels of MUC-1 mucin expression at the protein and/or mRNA level. Compositions for modulating immune function contain compounds that modulate the expression or function of MUC-1. Methods of treating disorders associated an inappropriate state of T-cell activation involve contacting a T-cell with a compound containing an inhibitor of MUC-1 expression or function.
    Type: Grant
    Filed: August 30, 2000
    Date of Patent: August 5, 2003
    Inventors: Babita Agrawal, B. Michael Longenecker
  • Lipid-modified muc-1 derivatives
    Patent number: 6600012
    Abstract: A method for generating a mixture of activated T-cells by combining a plurality of peripheral blood lymphocytes (PBLs) with an antigen-loaded liposome to produce antigen-loaded PBLs, and combining the antigen-loaded PBLs with a naive, anergic or memory T-cell, to produce an activated T-cell. Such activation is carried out in vivo or in vitro. The antigen-loaded PBLs and activated T-cells, prepared according to the methods of invention, have use as cellular vaccines for treatment of cancer and viral diseases.
    Type: Grant
    Filed: February 3, 2000
    Date of Patent: July 29, 2003
    Assignee: Biomira, Inc.
    Inventors: Babita Agrawal, Mark J. Krantz, Mark A. Reddish, B. Michael Longenecker
  • Enhancement of the cellular immune response
    Patent number: 6582697
    Abstract: DTH-Effector cells are primed with carbohydrate antigens and used to enhance the cellular immune response. Tumors have been inhibited by DTH-Effector cells primed with epiglycanin and with synthetic T and Tn antigens. Either the DTH-Effector cells, or these tumor-associated carbohydrate antigens directly, may be used for tumor prophylaxis and therapy.
    Type: Grant
    Filed: November 7, 2001
    Date of Patent: June 24, 2003
    Assignee: Biomira, Inc.
    Inventors: B. Michael Longenecker, Carina Henningsson
  • MUC-1 antagonists and methods of treating immune disorders
    Publication number: 20020142983
    Abstract: The invention provides compounds and compositions of containing intracellular inhibitors of the mucin MUC-1. These intracellular MUC-1 inhibitors are exemplified by protein-based inhibitors that contain a targeting and/or an internalization domain, and by antisense nucleic acids. These inhibitors are useful in methods of treating autoimmune disorders.
    Type: Application
    Filed: October 29, 2001
    Publication date: October 3, 2002
    Applicant: BIOMIRA, INC.
    Inventors: Babita Agrawal, B. Michael Longenecker
  • Enhancement of the cellular immune response
    Publication number: 20020068071
    Abstract: DTH-Effector cells are primed with carbohydrate antigens and used to enhance the cellular immune response. Tumors have been inhibited by DTH-Effector cells primed with epiglycanin and with synthetic T and Tn antigens. Either the DTH-Effector cells, or these tumor-associated carbohydrate antigens directly, may be used for tumor prophylaxis and therapy.
    Type: Application
    Filed: November 7, 2001
    Publication date: June 6, 2002
    Inventors: B. Michael Longenecker, Carina Henningsson
  • MUC-1 as an immunosuppressive therapeutic agent for the treatment of inflammatory and autoimmune conditions
    Publication number: 20020044943
    Abstract: The invention relates to novel methods of treatment and pharmaceutical compositions comprising the mucin MUC-1 and its derivatives. Preferred MUC-1 derivatives comprise multiple tandem repeats of the MUC-1 core sequence. The disclosed compositions and methods are particularly useful in treating autoimmune disorders, inflammatory disorders, organ transplant rejection and graft versus host disease.
    Type: Application
    Filed: August 13, 2001
    Publication date: April 18, 2002
    Inventors: B. Michael Longenecker, Judith C. Hugh, Lyle H. Regimbald
  • Enhancement of the cellular immune response
    Patent number: RE38046
    Abstract: DTH-Effector cells are printed with carbohydrate antigens and used to enhance the cellular immune response. Tumors have been inhibited by DTH-Effector cells primed with epiglycanin and with synthetic T and Tn antigens. Either the DTH-Effector cells, or these tumor-associated carbohydrate antigens directly, may be used for tumor prophylaxis and therapy.
    Type: Grant
    Filed: August 25, 2000
    Date of Patent: March 25, 2003
    Assignee: Biomira, Inc.
    Inventors: B. Michael Longenecker, Carina Henningsson